Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
Sponsor
National Center for Research Resources (NCRR) (NIH)
Overall Status
Completed
CT.gov ID
NCT00004359
Collaborator
Northwestern University (Other)
10
Study Details
Study Description
Brief Summary
OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita.
- Investigate the effect of ECP on lymphocyte activity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days.
Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Study Start Date
:
Feb 1, 1996
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
- Active epidermolysis bullosa acquisita
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- National Center for Research Resources (NCRR)
- Northwestern University
Investigators
- Study Chair: Kenneth B. Gordon, Northwestern University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00004359
Other Study ID Numbers:
- 199/11928
- NU-511
First Posted:
Oct 19, 1999
Last Update Posted:
Jun 24, 2005
Last Verified:
Jan 1, 2000
Keywords provided by ,
,
Additional relevant MeSH terms: